Immunic Showcases Research Advancements at Key September Scientific Conferences

Immunic Highlights Key Presentations at Upcoming Scientific Conferences

Immunic, Inc., a biotechnology firm dedicated to developing oral therapies for chronic inflammatory and autoimmune diseases, is set to showcase significant advancements in its research at several notable conferences this September. Among these, the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, will feature a comprehensive overview by President and COO Jason Tardio. This presentation, accessible via the conference portal starting September 5, serves as a platform for Immunic to communicate its strategic vision and ongoing projects to potential investors and industry stakeholders.

Following this event, Dr. Daniel Vitt, CEO of Immunic, alongside Tardio and Jessica Breu, Vice President of Investor Relations and Communications, will engage in one-on-one meetings with investors. These discussions aim to deepen relationships and foster understanding of Immunic's innovative pipeline, particularly its lead asset, vidofludimus calcium (IMU-838). This engagement highlights the company's commitment to transparency and proactive communication, essential elements for building investor confidence in the biotech sector.

Immunic's presence at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), occurring from September 24-26 in Barcelona, is particularly noteworthy. The company plans to present pivotal data on vidofludimus calcium, especially its efficacy and safety in treating progressive forms of multiple sclerosis. An oral presentation titled "Efficacy and Safety of Vidofludimus Calcium, a Novel Nurr1 Activator and Selective DHODH Inhibitor, in Progressive Multiple Sclerosis" is scheduled for September 24 at 2:35 PM CEST. Additionally, a late-breaking poster presentation will delve into the findings from the Phase 2 CALLIPER Trial, specifically addressing subpopulation data for Primary Progressive Multiple Sclerosis. Immunic's booth (#B37) at the conference will serve as a hub for discussions and inquiries regarding these promising results.

As Immunic prepares for these significant engagements, the company emphasizes its focus on advancing treatments that address critical unmet needs in chronic inflammatory and autoimmune diseases. The planned presentations and interactions at these conferences are strategic moves to enhance visibility and foster collaborations within the scientific community, which could accelerate the development and approval of their therapeutic candidates.

In summary, Immunic's participation in these conferences not only underscores its dedication to scientific excellence but also reflects its efforts to strengthen relationships with investors and the medical research community. With the upcoming presentations, the company aims to position itself as a key player in the ongoing quest for effective therapies for chronic inflammatory conditions, particularly multiple sclerosis.